The Gynecologic Oncology Group
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
- Conditions
- Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Endometrioid Adenocarcinoma, Variant With Squamous DifferentiationRecurrent Uterine Corpus CarcinomaStage I Uterine Corpus CancerStage II Uterine Corpus CancerStage III Uterine Corpus CancerStage IV Uterine Corpus Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 75
- Registration Number
- NCT00064025
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00023907
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00004037
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
- Conditions
- Sarcoma
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00003054
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- First Posted Date
- 2003-05-19
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005861
- Locations
- 🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Brookview Research, Inc., Nashville, Tennessee, United States
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 71
- Registration Number
- NCT00017134
- Locations
- 🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸St. John's Regional Health Center, Springfield, Missouri, United States
🇺🇸Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Ovarian Serous CystadenocarcinomaPrimary Peritoneal CarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Brenner TumorFallopian Tube CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Mucinous CystadenocarcinomaStage III Ovarian CancerStage IV Ovarian Cancer
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 32
- Registration Number
- NCT00060359
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
- Conditions
- Cervical Cancer
- First Posted Date
- 2003-05-05
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005837
- Locations
- 🇺🇸
CCOP - Columbia River Program, Portland, Oregon, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-04-29
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005836
- Locations
- 🇺🇸
Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States
🇺🇸Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
- Conditions
- Gestational Trophoblastic TumorNeurotoxicityPeripheral NeuropathyUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 100
- Registration Number
- NCT00058071
- Locations
- 🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States